a) FDOJ (fatty-degenerative Osteolysis/Osteonecrosis of the Jawbone) is characterized by the absence of the usual clinical parameters of local tooth and jaw pain, with the exception of the more diffuse atypical facial pain (FDOJ is in these pain cases called “NICO”) and the radiographic inconspicuousness.
(Literatur: Lechner, J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clinical, Cosmetic and Investigational Dentistry 2014:6 71–79..: https://www.dovepress.com/articles.php?article_id=18049&l=bBexMykzNGYEHIPfWZ1MT6xu198194
b) FDOJ is morphologically and macroscopically characterized by a fatty-degenerative dissolution of the spongiosal jawbone with conspicuous structural softening and osteolysis.
(Literature: Lechner J, von Baehr V. Chemokine RANTES/CCL5 as an unknown link between wound healing in the jawbone and systemic disease: is prediction and tailored treatments in the horizon? EPMA Journal.2015, 6:10. DOI: 10.1186/s13167-015-0032-4
EPMA Journal 2015, 6:10 (Section: Traditional, Complementary and Alternative Medicine)
c) FDOJ shows the typically excessive signaling of the proinflammatory chemokine RANTES / CCL5 in almost all areas examined.
(Literatur: Lechner J, von Baehr V. “RANTES and fibroblast growth factor 2 in jawbone cavitations triggers for systemic disease”.
d) Our research indicates that overactivated signal transduction cascades may be specific to RANTES / CCL5 in radiologically unrecognized FDOJ sites in association with RANTES / CCL5 effects in complex chronic diseases. For the first time, we present a scientifically validated explanatory model of the so-called “disturbance field effect” from jawbone area.
(Literature: Lechner J, von Baehr V. Journal of Breast Cancer: Basic and Clinical Research: „Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients—Case Report and Research”.
Free download: https://la-press.com/article.php?article_id=4214. )
However, in a literature review, the modern knowledge gained on the pathophysiological role of the chemokine RANTES / CCL5 in systemic diseases contrasts with minimal hits in relation to RANTES / CCL5 from FDOK areas: Are keywords in the search engine GoogleScholar for 22 diseases and their connection to RANTES / CCL5 “Allergy AND RANTES CCL5” hits 9,500, “Cancer Reviews AND RANTES CCL5” 9,410, “Rheumatoid Arthritis AND RANTES CCL5” 7,310, “Colon Cancer” 6,330, ” Breast Cancer, etc. “to 5,150,” Multiple Sclerosis, etc. “to 5,140,” Pancreas Carcinoma, etc. “to 4,180,” Melanoma, etc. “to 3,940,” Breast Cancer Metastasis, etc. “to 3,750,” Prostate Cancer, etc. “at 3,480,” Depression, etc. “at 2,440,” Alzheimer Disease, etc. “at 2,190,” Thyroid, etc. “at 1,940,” Thyroid, etc. “at 1,940,” Hodgkin, etc. ” “Au f 1,770, “Non-Hodgkin, etc.” to 1,750, “Parkinson’s Disease, etc.” to 1,370, “Periodontitis, etc.” to 942, “Opioid Receptor, etc.” to 862, “ALS, etc.” on 556, on “Lichen Planus, etc.” on 356, on “Trigeminal Neuralgia, etc.” on 227, on “Jawbone, etc.” on 32, of which 14 are their own publications.